Anti-VEGF treatment of macular edema associated with retinal vein occlusion: patterns of use and effectiveness in clinical practice (ECHO study report 2)

References

• RogersSMcIntoshRLCheungNThe prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and AustraliaOphthalmology20101172313319.e120022117
   PubMed Web of Science ®Google Scholar
• JaulimAAhmedBKhanamTChatziralliIPBranch retinal vein occlusion: epidemiology, pathogenesis, risk factors, clinical features, diagnosis, and complications. An update of the literatureRetina201333590191023609064
   PubMed Web of Science ®Google Scholar
• McIntoshRLRogersSLLimLNatural history of central retinal vein occlusion: an evidence-based systematic reviewOphthalmology2010117611131123.e1520430446
   PubMed Web of Science ®Google Scholar
• HayrehSSPodhajskyPAZimmermanMBCentral and hemicentral retinal vein occlusion: role of anti–platelet aggregation agents and anticoagulantsOphthalmology201111881603161121704382
   PubMed Web of Science ®Google Scholar
• BrownDMCampochiaroPABhisitkulRBSustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III studyOphthalmology201111881594160221684606
   PubMed Web of Science ®Google Scholar
• ThachABYauLHoangCTuomiLTime to clinically significant visual acuity gains after ranibizumab treatment for retinal vein occlusion: BRAVO and CRUISE trialsOphthalmology201412151059106624424249
   PubMed Web of Science ®Google Scholar
• BrownDMHeierJSClarkWLIntravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS studyAm J Ophthalmol20131553429437.e723218699
   PubMed Web of Science ®Google Scholar
• YehWSHallerJALanzettaPEffect of the duration of macular edema on clinical outcomes in retinal vein occlusion treated with dexamethasone intravitreal implantOphthalmology201211961190119822361318
   PubMed Web of Science ®Google Scholar
• SteinbrookRThe price of sight–ranibizumab, bevacizumab, and the treatment of macular degenerationN Engl J Med2006355141409141217021315
   PubMed Web of Science ®Google Scholar
• PapadopoulosNMartinJRuanQBinding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumabAngiogenesis201215217118522302382
   PubMed Web of Science ®Google Scholar
• CampochiaroPAHeierJSFeinerLRanibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III studyOphthalmology2010117611021112.e120398941
   PubMed Web of Science ®Google Scholar
• CampochiaroPABrownDMAwhCCSustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III studyOphthalmology2011118102041204921715011
   PubMed Web of Science ®Google Scholar
• ClarkWLBoyerDSHeierJSIntravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT studyOphthalmology2016123233033626522708
   PubMed Web of Science ®Google Scholar
• HeierJSClarkWLBoyerDSIntravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS studyOphthalmology2014121714141420.e124679444
   PubMed Web of Science ®Google Scholar
• KorobelnikJFHolzFGRoiderJIntravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one-year results of the phase 3 GALILEO studyOphthalmology2014121120220824084497
   PubMed Web of Science ®Google Scholar
• HolekampNMLiuYYehWSClinical utilization of anti-VEGF agents and disease monitoring in neovascular age-related macular degenerationAm J Ophthalmol20141574825.e1833.e124388973
   PubMed Web of Science ®Google Scholar
• KissSLiuYBrownJClinical utilization of anti-vascular endothelial growth-factor agents and patient monitoring in retinal vein occlusion and diabetic macular edemaClin Ophthalmol201481611162125210429
   PubMedGoogle Scholar
• BlinderKJDugelPUChenSAnti-VEGF treatment of diabetic macular edema in clinical practice: effectiveness and patterns of use (ECHO study report 1)Clin Ophthalmol20171139340128260851
   PubMed Web of Science ®Google Scholar
• GregoriNZFeuerWRosenfeldPJNovel method for analyzing Snellen visual acuity measurementsRetina20103071046105020559157
   PubMed Web of Science ®Google Scholar
• Risk factors for central retinal vein occlusionThe Eye Disease Case-Control Study GroupArch Ophthalmol199611455455548619763
   PubMedGoogle Scholar
• NarayananRPanchalBDasTA randomised, double-masked, controlled study of the efficacy and safety of intravitreal bevacizumab versus ranibizumab in the treatment of macular oedema due to branch retinal vein occlusion: MARVEL report no. 1Br J Ophthalmol201599795495925631483
   PubMed Web of Science ®Google Scholar
• RajagopalRShahGKBlinderKJBevacizumab versus ranibi-zumab in the treatment of macular edema due to retinal vein occlusion: 6-month results of the CRAVE studyOphthalmic Surg Lasers Imaging Retina201546884485026431300
   PubMed Web of Science ®Google Scholar
• YuanAAhmadBUXuDComparison of intravitreal ranibizumab and bevacizumab for the treatment of macular edema secondary to retinal vein occlusionInt J Ophthalmol201471869124634869
   PubMed Web of Science ®Google Scholar
• KhanMWaiKMSilvaFQComparison of ranibizumab and bevacizumab for macular edema secondary to retinal vein occlusions in routine clinical practiceOphthalmic Surg Lasers Imaging Retina201748646547228613352
   PubMed Web of Science ®Google Scholar
• ScottIUVanVeldhuisenPCIpMSEffect of bevacizumab vs. aflibercept on visual acuity among patients with macular edema due to central retinal vein occlusion: the SCORE2 randomized clinical trialJAMA2017317202072208728492910
   PubMed Web of Science ®Google Scholar
• WeckerTEhlkenCBühlerAFive-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNVBr J Ophthalmol2017101335335927215744
   PubMed Web of Science ®Google Scholar
• BhisitkulRBCampochiaroPAShapiroHRubioRGPredictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomographyOphthalmology201312051057106323415775
   PubMed Web of Science ®Google Scholar
• PapakostasTDLimLvan ZylTIntravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizumabEye2016301798426449196
   PubMed Web of Science ®Google Scholar
• KonidarisVAl-HubeshyZTsaousisKTGorgoliKBanerjeeSEmpeslidisTOutcomes of switching treatment to aflibercept in patients with macular oedema secondary to central retinal vein occlusion refractory to ranibizumabInt Ophthalmol Epub1242017
   Web of Science ®Google Scholar
• ChatziralliITheodossiadisGMoschosMMMitropoulosPTheodossiadisPRanibizumab versus aflibercept for macular edema due to central retinal vein occlusion: 18-month results in real-life dataGraefes Arch Clin Exp Ophthalmol201725561093110028214955
   PubMed Web of Science ®Google Scholar
• RegnierSALarsenMBezlyakVAllenFComparative efficacy and safety of approved treatments for macular oedema secondary to branch retinal vein occlusion: a network meta-analysisBMJ Open201556e007527
   Web of Science ®Google Scholar
• WangJKSuPYHsuYRChenYJChenFTTsengYYComparison of the efficacy of intravitreal aflibercept and bevacizumab for macular edema secondary to branch retinal vein occlusionJ Ophthalmol20162016842194027190640
   PubMed Web of Science ®Google Scholar